INVESTIGADORES
MANUCHA Walter Ariel Fernando
congresos y reuniones científicas
Título:
Serum inflammatory mediators as potential biomarkers of heart failure associated or not with secondary pulmonary hypertension
Autor/es:
VIRNA MARTÍN GIMENÉZ; RAÚL SANZ; LUCIANA MAZZEI; ROBERTO BONAFEDE; WALTER MANUCHA
Lugar:
San Luis
Reunión:
Congreso; XXXIX Reunión Científica Anual organizada por la Sociedad de Biología de Cuyo; 2021
Resumen:
Cardiovascular disease (CVD), especially heart failure (HF) as its common final pathway, is the leading cause of morbidity and mortality worldwide. Furthermore, oxidative and inflammatory processes represent fundamental underlying mechanisms for the development and progression of HF. Of interest, in recent years the development of markers with diagnostic and prognostic value for this pathology and other related CVD has been revalued. Therefore, the objective of the present study was to quantify and evaluate inflammatory markers such as ultrasensitive CRP, IL-6, TNF-α and Hsp70 in the serum of patients with heart failure (HF) and to compare them with healthy individuals, also correlating the values obtained with oxidative stress markers and nitric oxide bioavailability previously investigated in these patients, as well as with the coexistence or not of secondary pulmonary hypertension (SPH) associated with HF. The determination of these mediators was achieved with standardized, reproducible, accurate and affordable biochemical methods. The values obtained for uCRP, IL-6 and TNF-α were in accordance with the pattern of oxidative markers previously found in these patients, thus exposing the coexistence of oxidative stress and inflammation during HF, but which is more exacerbated even when it is associated with SPH, which it finds would increase its value as a biomarker in this pathology. However, the found levels of Hsp70 were controversial. Therefore, additional studies are needed to assess in greater detail the importance of the relationship between serum Hsp70 expression and SPH-associated or non-SPH morbidity in HF.